Pinnacle Wealth Management Advisory Group’s Acumen Pharmaceuticals ABOS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$40K Buy
18,021
+1
+0% +$3 ﹤0.01% 546
2026
Q2
$48.1K Hold
18,020
– – ﹤0.01% 560
2026
Q1
$42.5K Hold
18,020
– – ﹤0.01% 538
2025
Q4
$38K Hold
18,020
– – ﹤0.01% 518
2025
Q3
$30.8K Hold
18,020
– – ﹤0.01% 395
2025
Q2
$20.9K Hold
18,020
– – ﹤0.01% 366
2025
Q1
$19.8K Hold
18,020
– – ﹤0.01% 358
2024
Q4
$31K Hold
18,020
– – ﹤0.01% 354
2024
Q3
$44.7K Hold
18,020
– – ﹤0.01% 357
2024
Q2
$43.6K Hold
18,020
– – ﹤0.01% 346
2024
Q1
$73K Buy
+18,020
New +$67.9K 0.01% 342
2023
Q4
– Sell
-18,020
Closed -$74.8K – 339
2023
Q3
$74.8K Hold
18,020
– – 0.01% 307
2023
Q2
$86.7K Buy
+18,020
New +$86.3K 0.01% 320

Other funds holding ABOS

Pinnacle Wealth Management Advisory Group's ABOS Position: Q3 2026 in Review

Pinnacle Wealth Management Advisory Group increased its Acumen Pharmaceuticals (ABOS) stake by 0.01% in Q3 2026, buying an estimated $3 and bringing the position to 18,021 shares worth $40K. The position accounts for ﹤0.01% of the portfolio, ranked #546.

Pinnacle Wealth Management Advisory Group first reported a position in ABOS in Q2 2023 and has held it in 13 quarters since. The position peaked at $86.7K in Q2 2023. 11 funds tracked by Wall St. Rank hold ABOS as of Q3 2026.

  • Pinnacle Wealth Management Advisory Group held 18,021 shares of Acumen Pharmaceuticals worth $40K as of Q3 2026.
  • Pinnacle Wealth Management Advisory Group bought 1 Acumen Pharmaceuticals share in Q3 2026, an estimated $3.
  • Acumen Pharmaceuticals made up ﹤0.01% of Pinnacle Wealth Management Advisory Group's portfolio in Q3 2026, its #546 holding.
  • Pinnacle Wealth Management Advisory Group first reported a position in Acumen Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
  • Pinnacle Wealth Management Advisory Group's Acumen Pharmaceuticals position peaked at $86.7K in Q2 2023.
  • 11 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q3 2026.

Based on Pinnacle Wealth Management Advisory Group's 13F filing for Q3 2026, filed 23 Oct 2026.